DK2776567T3 - Sammensætninger og fremgangsmåder til behandling af cytomegalovirus. - Google Patents

Sammensætninger og fremgangsmåder til behandling af cytomegalovirus. Download PDF

Info

Publication number: DK2776567T3
Authority: DK; Denmark
Prior art keywords: cytomegalovirus; compositions; treatment; methods
Prior art date: 2011-11-11

Application number

DK12847559.7T

Other languages

English (en)

Inventor

David E Anderson

Anne-Catherine Fluckiger

Original Assignee

Variation Biotechnologies Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-11

Filing date

2012-11-09

Publication date

2021-04-26

2012-11-09 Application filed by Variation Biotechnologies Inc filed Critical Variation Biotechnologies Inc

2021-04-26 Application granted granted Critical

2021-04-26 Publication of DK2776567T3 publication Critical patent/DK2776567T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20245—Special targeting system for viral vectors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Lubricants (AREA)

DK12847559.7T 2011-11-11 2012-11-09 Sammensætninger og fremgangsmåder til behandling af cytomegalovirus. DK2776567T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161558800P	2011-11-11	2011-11-11
US201261654157P	2012-06-01	2012-06-01
PCT/IB2012/002854 WO2013068847A2 (en)	2011-11-11	2012-11-09	Compositions and methods for treatment of cytomegalovirus

Publications (1)

Publication Number	Publication Date
DK2776567T3 true DK2776567T3 (da)	2021-04-26

Family

ID=48290708

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK12847559.7T DK2776567T3 (da)	2011-11-11	2012-11-09	Sammensætninger og fremgangsmåder til behandling af cytomegalovirus.

Country Status (14)

Country	Link
US (3)	US9777043B2 (da)
EP (2)	EP2776567B1 (da)
JP (2)	JP6232544B2 (da)
KR (2)	KR102340558B1 (da)
CN (3)	CN104271745A (da)
AU (3)	AU2012335277B2 (da)
BR (2)	BR112014011229B1 (da)
CA (2)	CA3166278A1 (da)
DK (1)	DK2776567T3 (da)
ES (1)	ES2874233T3 (da)
MX (1)	MX353189B (da)
PT (1)	PT2776567T (da)
RU (2)	RU2737530C1 (da)
WO (1)	WO2013068847A2 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3936606A1 (en)	2009-06-18	2022-01-12	Kiyatec Inc.	Bioreactor system
EP2600901B1 (en)	2010-08-06	2019-03-27	ModernaTX, Inc.	A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
MX2013003681A (es)	2010-10-01	2013-11-20	Moderna Therapeutics Inc	Ácidos nucleicos manipulados y métodos de uso de los mismos.
DE12722942T1 (de)	2011-03-31	2021-09-30	Modernatx, Inc.	Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
KR102014061B1 (ko)	2011-10-03	2019-08-28	모더나 세라퓨틱스, 인코포레이티드	변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
PT2776567T (pt)	2011-11-11	2021-05-25	Variation Biotechnologies Inc	Composições e métodos para o tratamento de citomegalovírus
JP2015501844A (ja)	2011-12-16	2015-01-19	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
KR102314245B1 (ko) *	2012-03-27	2021-10-20	배리에이션 바이오테크놀로지스 아이엔씨.	항-사이토메갈로바이러스 중화 항체를 탐지하기 위한 방법
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en)	2012-04-02	2018-01-30	Modernatx, Inc.	Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015518704A (ja)	2012-04-02	2015-07-06	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	膜タンパク質の産生のための修飾ポリヌクレオチド
EP3269388A1 (en) *	2012-10-30	2018-01-17	Pfizer Inc.	Recombinant particle based vaccines against human cytomegalovirus infection
HRP20220607T1 (hr)	2012-11-26	2022-06-24	Modernatx, Inc.	Terminalno modificirana rna
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US10023626B2 (en)	2013-09-30	2018-07-17	Modernatx, Inc.	Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en)	2013-10-03	2015-04-09	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
ES2736500T3 (es)	2014-06-18	2020-01-02	Morphosys Ag	Proteínas de fusión y usos de las mismas
KR101678740B1 (ko) *	2014-10-24	2016-11-23	단국대학교 천안캠퍼스 산학협력단	세포 부착활성 및 골분화 촉진활성을 나타내는 피브로넥틴 융합단백질
US12060391B2 (en)	2015-03-16	2024-08-13	The Broad Institute, Inc.	Constructs for continuous monitoring of live cells
US10968253B2 (en)	2015-10-20	2021-04-06	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Methods and products for genetic engineering
WO2017070613A1 (en)	2015-10-22	2017-04-27	Modernatx, Inc.	Human cytomegalovirus vaccine
US10611800B2 (en)	2016-03-11	2020-04-07	Pfizer Inc.	Human cytomegalovirus gB polypeptide
WO2017162265A1 (en) *	2016-03-21	2017-09-28	Biontech Rna Pharmaceuticals Gmbh	Trans-replicating rna
EP3528821A4 (en)	2016-10-21	2020-07-01	ModernaTX, Inc.	VACCINE AGAINST THE HUMANE CYTOMEGALOVIRUS
EP3784276A4 (en)	2018-04-24	2022-03-16	Merck Sharp & Dohme Corp.	SCALABLE CHROMATOGRAPHY METHOD FOR THE PURIFICATION OF HUMAN CYTOMEGALOVIRUS
SG11202010821TA (en) *	2018-05-04	2020-11-27	Spybiotech Ltd	Vaccine composition
US11629172B2 (en)	2018-12-21	2023-04-18	Pfizer Inc.	Human cytomegalovirus gB polypeptide
BR112021024157A2 (pt) *	2019-05-31	2022-04-26	Variation Biotechnologies Inc	Composições imunoterapêuticas para tratamento de glioblastoma multiforme
US20210069321A1 (en)	2019-09-09	2021-03-11	Glaxosmithkline Biologicals Sa	Immunotherapeutic compositions
TW202413391A (zh)	2020-06-21	2024-04-01	美商輝瑞股份有限公司	人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
US11406703B2 (en)	2020-08-25	2022-08-09	Modernatx, Inc.	Human cytomegalovirus vaccine
CN115948468A (zh) *	2022-09-09	2023-04-11	青岛大学	一种人巨细胞病毒重组载体及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6267965B1 (en)	1981-12-24	2001-07-31	Virogenetics Corporation	Recombinant poxvirus—cytomegalovirus compositions and uses
JPS61103895A (ja) *	1984-10-26	1986-05-22	Green Cross Corp:The	ＨＢｓＡｇの精製方法
EP0436537A4 (en) *	1988-01-29	1992-04-08	Chiron Corporation	Recombinant cmv neutralizing proteins
US5500161A (en)	1993-09-21	1996-03-19	Massachusetts Institute Of Technology And Virus Research Institute	Method for making hydrophobic polymeric microparticles
DE19856463B4 (de) *	1998-11-26	2006-02-02	Heinrich-Pette-Institut	Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren
DE19910044A1 (de)	1999-03-08	2000-09-14	Bodo Plachter	Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
AU782676B2 (en) *	1999-09-30	2005-08-18	Corixa Corporation	Immunologically significant herpes simplex virus antigens
EP1201750A1 (en) *	2000-10-26	2002-05-02	Genopoietic	Synthetic viruses and uses thereof
US9045727B2 (en) *	2002-05-17	2015-06-02	Emory University	Virus-like particles, methods of preparation, and immunogenic compositions
ES2429338T3 (es)	2002-12-23	2013-11-14	Vical Incorporated	Vacuna basada en polinucleótidos optimizados por codones contra infección por citomegalovirus humano
ATE432285T1 (de)	2003-07-11	2009-06-15	Alphavax Inc	Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
RU2290204C1 (ru) *	2005-07-27	2006-12-27	Общество с ограниченной ответственностью "Аванген"	Рекомбинантный гибридный белок, препарат для иммунотерапии на его основе и способ иммунотерапии рецидивирующего папилломатоза гортани
US20100047266A1 (en)	2006-07-27	2010-02-25	Ligocyte Pharmaceuticals, Inc.	Chimeric virus-like particles
US20090123494A1 (en) *	2007-07-31	2009-05-14	William Staplin	Momlv-based pseudovirion packaging cell line
WO2009120883A2 (en) *	2008-03-26	2009-10-01	Life Technologies Corporation	Virus-like particle mediated cellular delivery
GB0907935D0 (en) *	2009-05-08	2009-06-24	Henderson Morley Plc	Vaccines
PT2776567T (pt)	2011-11-11	2021-05-25	Variation Biotechnologies Inc	Composições e métodos para o tratamento de citomegalovírus
WO2015089340A1 (en) *	2013-12-11	2015-06-18	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Human herpesvirus trimeric glycoprotein b, protein complexes comprising trimeric gb and their use as vaccines

2012
- 2012-11-09 PT PT128475597T patent/PT2776567T/pt unknown
- 2012-11-09 RU RU2014123465A patent/RU2737530C1/ru active
- 2012-11-09 CN CN201280066355.XA patent/CN104271745A/zh active Pending
- 2012-11-09 RU RU2019139064A patent/RU2019139064A/ru unknown
- 2012-11-09 KR KR1020197025818A patent/KR102340558B1/ko active IP Right Grant
- 2012-11-09 CN CN202010272504.4A patent/CN111995664B/zh active Active
- 2012-11-09 ES ES12847559T patent/ES2874233T3/es active Active
- 2012-11-09 WO PCT/IB2012/002854 patent/WO2013068847A2/en active Application Filing
- 2012-11-09 CA CA3166278A patent/CA3166278A1/en active Pending
- 2012-11-09 BR BR112014011229-0A patent/BR112014011229B1/pt active IP Right Grant
- 2012-11-09 JP JP2014540570A patent/JP6232544B2/ja active Active
- 2012-11-09 CA CA2889659A patent/CA2889659C/en active Active
- 2012-11-09 US US14/357,423 patent/US9777043B2/en active Active
- 2012-11-09 MX MX2014005653A patent/MX353189B/es active IP Right Grant
- 2012-11-09 CN CN201711042348.7A patent/CN107875382B/zh active Active
- 2012-11-09 EP EP12847559.7A patent/EP2776567B1/en active Active
- 2012-11-09 BR BR122019027913-6A patent/BR122019027913B1/pt active IP Right Grant
- 2012-11-09 DK DK12847559.7T patent/DK2776567T3/da active
- 2012-11-09 KR KR1020147015909A patent/KR102301463B1/ko active IP Right Grant
- 2012-11-09 AU AU2012335277A patent/AU2012335277B2/en active Active
- 2012-11-09 EP EP21152309.7A patent/EP3854416A1/en active Pending
2017
- 2017-08-04 JP JP2017151540A patent/JP6657150B2/ja active Active
- 2017-08-22 US US15/683,355 patent/US11248026B2/en active Active
2018
- 2018-05-18 AU AU2018203538A patent/AU2018203538A1/en not_active Abandoned
2020
- 2020-11-03 AU AU2020264275A patent/AU2020264275B2/en active Active
2022
- 2022-02-11 US US17/670,052 patent/US20230272013A1/en active Pending

Also Published As

Publication number	Publication date
CA3166278A1 (en)	2013-05-16
JP2018023374A (ja)	2018-02-15
WO2013068847A3 (en)	2014-10-30
US11248026B2 (en)	2022-02-15
KR20190104644A (ko)	2019-09-10
BR122019027913B1 (pt)	2021-11-30
CN104271745A (zh)	2015-01-07
CA2889659A1 (en)	2013-05-16
AU2018203538A1 (en)	2018-06-07
BR112014011229A2 (pt)	2017-05-09
CA2889659C (en)	2023-03-14
JP2015505299A (ja)	2015-02-19
EP2776567A4 (en)	2015-12-30
KR20140095556A (ko)	2014-08-01
RU2019139064A (ru)	2020-01-27
BR112014011229B1 (pt)	2021-10-13
ES2874233T3 (es)	2021-11-04
CN107875382B (zh)	2024-03-08
US20230272013A1 (en)	2023-08-31
CN111995664A (zh)	2020-11-27
EP3854416A1 (en)	2021-07-28
WO2013068847A2 (en)	2013-05-16
KR102301463B1 (ko)	2021-09-14
US9777043B2 (en)	2017-10-03
AU2020264275A1 (en)	2020-11-26
AU2020264275B2 (en)	2023-12-14
EP2776567B1 (en)	2021-01-20
CN111995664B (zh)	2024-08-02
JP6232544B2 (ja)	2017-11-22
US20170349634A1 (en)	2017-12-07
AU2012335277A1 (en)	2014-06-12
US20140308308A1 (en)	2014-10-16
AU2012335277B2 (en)	2018-06-14
CN107875382A (zh)	2018-04-06
MX2014005653A (es)	2014-09-04
JP6657150B2 (ja)	2020-03-04
MX353189B (es)	2018-01-05
EP2776567A2 (en)	2014-09-17
PT2776567T (pt)	2021-05-25
KR102340558B1 (ko)	2021-12-21
RU2737530C1 (ru)	2020-12-03

Publication	Publication Date	Title
DK2776567T3 (da)	2021-04-26	Sammensætninger og fremgangsmåder til behandling af cytomegalovirus.
DK2929031T5 (da)	2021-08-23	Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK3252160T3 (da)	2021-02-01	Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation
DK2898061T3 (da)	2020-02-10	Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2699553T3 (da)	2024-01-29	Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed
DK3444342T3 (da)	2020-08-24	Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
DK2739293T3 (da)	2020-08-24	Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK2890780T3 (da)	2020-09-21	Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
DK2768321T3 (da)	2020-08-31	Fremgangsmåder og sammensætninger til induktion af mæthed
DK3597749T5 (da)	2024-09-02	Fremgangsmåder og sammensætninger til rna-dirigeret mål-dna-modificering og til rna-dirigeret modulering af transkription
DK3520805T3 (da)	2021-04-19	Sammensætninger til behandling af myelofibrose
DK2691443T3 (da)	2021-05-03	Konjugerede lipomerer og anvendelser af disse
DK2688557T3 (da)	2017-11-27	Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
DK2872153T3 (da)	2019-05-20	Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf
DK2763665T3 (da)	2019-11-18	Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
DK3495392T3 (da)	2021-09-13	Anti-cgrp-sammensætninger og anvendelse deraf
DK4082530T3 (da)	2024-05-06	Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme
DK2811876T4 (da)	2024-04-15	Kaffemaskine og fremgangsmåde til betjening af samme
DK3412687T3 (da)	2020-05-11	Fremgangsmåder til behandling af dlbcl
DK2987507T3 (da)	2023-04-03	Fremgangsmåder til behandling af degenerative knogletilstande
DK3071215T3 (da)	2020-03-23	Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension
DK3366307T3 (da)	2021-11-01	Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
DK3007695T3 (da)	2024-03-18	Sammensætninger og fremgangsmåder til behandling af anæmi
DK2771022T3 (da)	2020-09-28	Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf
DK2723347T3 (da)	2019-11-18	Forebyggelse og behandling af inflammationstilstande